

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM863255

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
ACERUS BIOPHARMA INC.		12/21/2023	Corporation: CANADA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	FIRST GENERATION CAPITAL INC.		
<b>Street Address:</b>	40 King Street West		
<b>City:</b>	Toronto, Ontario		
<b>State/Country:</b>	CANADA		
<b>Postal Code:</b>	M5H 3Y		
<b>Entity Type:</b>	Corporation: CANADA		
<b>PROPERTY NUMBERS Total: 5</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	90095710	TESTOSTEROWN	
<b>Serial Number:</b>	88830833	TRIVAIR	
<b>Serial Number:</b>	97593472	TRIVAIR DEPOSITION SYSTEM	
<b>Serial Number:</b>	90002018	NATESTO N	
<b>Serial Number:</b>	86084664	NATESTO	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	9495676710		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	9498527792		
<b>Email:</b>	ipprosecution@orrick.com, vsantos@orrick.com, amosley@orrick.com		
<b>Correspondent Name:</b>	ORRICK, HERRINGTON & SUTCLIFFE LLP		
<b>Address Line 1:</b>	2050 Main Street, Suite 1100		
<b>Address Line 4:</b>	Irvine, CALIFORNIA 92614-8255		
<b>ATTORNEY DOCKET NUMBER:</b>	52456.2		
<b>NAME OF SUBMITTER:</b>	Asheli Mosley		
<b>SIGNATURE:</b>	/Asheli Mosley/		
<b>DATE SIGNED:</b>	12/22/2023		
<b>Total Attachments: 6</b>			

CH \$140.00 90095710

source=FGC-APC - Trademark Security Agreement (Acerus Biopharma) (2023) [Executed]#page1.tif  
source=FGC-APC - Trademark Security Agreement (Acerus Biopharma) (2023) [Executed]#page2.tif  
source=FGC-APC - Trademark Security Agreement (Acerus Biopharma) (2023) [Executed]#page3.tif  
source=FGC-APC - Trademark Security Agreement (Acerus Biopharma) (2023) [Executed]#page4.tif  
source=FGC-APC - Trademark Security Agreement (Acerus Biopharma) (2023) [Executed]#page5.tif  
source=FGC-APC - Trademark Security Agreement (Acerus Biopharma) (2023) [Executed]#page6.tif

## TRADEMARK SECURITY AGREEMENT

This **TRADEMARK SECURITY AGREEMENT**, dated as of December 21, 2023 (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), is made by the entity identified as a grantor on the signature pages hereto (the “Grantor”) in favor of First Generation Capital Inc., as the secured party (in such capacity together with its successors and permitted assigns, the “Secured Party”).

**WHEREAS** the Grantor is party to a general security agreement, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Security Agreement”), between the Grantor and the Secured Party pursuant to which the Grantor granted a security interest to the Secured Party in the Trademark Collateral (as defined below) and is required to execute and deliver this Agreement.

**NOW, THEREFORE**, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantor hereby agrees with the Secured Party as follows:

### **SECTION 1. DEFINED TERMS**

Unless otherwise defined herein, terms used herein shall have the meanings given to them in the Security Agreement or the Loan Agreement (as defined in the Security Agreement), as applicable.

### **SECTION 2. GRANT OF SECURITY INTEREST**

**SECTION 2.1** Scope of Grant. The Grantor, as security for the payment and performance in full of the Secured Obligations of the Grantor, hereby pledges to the Secured Party, and hereby grants to the Secured Party, a security interest in all right, title and interest in or to any and all of the following assets and properties now owned or at any time hereafter acquired by the Grantor or in which the Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the “Trademark Collateral”):

(i) all trademarks, trade names, corporate names, company names, business names, fictitious business names, internet domain names, trade styles, service marks, logos, other business identifiers, whether registered or unregistered, all registrations and recordings thereof, and all applications in connection therewith (other than each application to register any trademark or service mark prior to the filing under Applicable Law of a verified statement of use for such trademark or service mark) anywhere in the United States, including, without limitation, registrations and registration applications in the United States Patent and Trademark Office (“USPTO”), including, without limitation, the registrations and registrations applications listed on Schedule A hereto,

(ii) all reissues, extensions, continuations (in whole or in part) and renewals of any of the foregoing,

(iii) all income, royalties, damages and payments now or hereafter due and/or payable under any of the foregoing or with respect to any of the foregoing, including, without limitation, damages or payments for past, present or future infringements of any of the foregoing,

(iv) the right to sue for past, present or future infringements of any of the foregoing,

(v) all rights corresponding to any of the foregoing (including, without limitation, the goodwill), and

(vi) to the extent not otherwise included, all Proceeds and products of any and all of the foregoing, all Accessions to any of the foregoing and all collateral security and Supporting Obligations (as now or hereafter defined in the UCC) given by any Person with respect to any of the foregoing;

**SECTION 2.2** Certain Limited Exclusions. Notwithstanding anything herein to the contrary, in no event shall the Trademark Collateral include or the security interest granted under Section 2.1 attach to any “intent-to-use” application for registration of a Trademark filed pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. § 1051, prior to the filing, and acceptance by the USPTO, of a “Statement of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto, solely to the extent, if any, that, and solely during the period, if any, in which, the grant of a security interest therein would impair the validity or enforceability of any registration that issues from such intent-to-use application under applicable federal law.

### **SECTION 3. SECURITY AGREEMENT**

The security interest granted pursuant to this Agreement is granted in conjunction with the security interest granted to the Secured Party pursuant to the Security Agreement, and the Grantor hereby acknowledges and affirms that the rights and remedies of the Secured Party with respect to the security interest in the Trademark Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event that any provision of this Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall control.

### **SECTION 4. RECORDATION**

The Grantor hereby authorizes and requests that the USPTO record this Agreement.

### **SECTION 5. TERMINATION**

At such time as the Secured Obligations shall have been paid in full in cash and the Facility has been terminated, the Trademark Collateral shall be released from the liens created hereby, and this Agreement and all obligations (other than those expressly stated to survive such termination) of the Secured Party and the Grantor shall terminate, all without delivery of any

instrument or performance of any act by any party, and all rights to the Trademark Collateral shall revert to the Grantor.

## **SECTION 6. GOVERNING LAW**

This Agreement and the other Loan Documents and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement or any other Loan Document (except, as to any other Loan Document, as expressly set forth therein) and the transactions contemplated hereby shall be governed by, and construed in accordance with, the law of the State of New York.


## **SECTION 7. COUNTERPARTS**

This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and shall be binding upon all parties, their successors and assigns, and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement or any document or instrument delivered in connection herewith by facsimile or in electronic (i.e., “pdf” or “tif”) format shall be effective as delivery of a manually executed counterpart of this Agreement or such other document or instrument, as applicable.

*[Remainder of page intentionally left blank]*

**IN WITNESS WHEREOF**, the Grantor has caused this Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

**ACERUS BIOPHARMA INC.**, as Grantor

By:   
Name: Naveed Manzoor  
Title: Chief Restructuring Officer

Acknowledged and Agreed:

**FIRST GENERATION CAPITAL INC.**, as the  
Secured Party

By: Ian Ihnatowycz  
Name: Ian Ihnatowycz  
Title: President & CEO

Schedule A to  
Trademark Security Agreement

**United States Trademarks of the Grantor**

Trademark	Serial or Registration Number
TESTOSTEROWN	90095710
TRIVAIR	88830833
TRIVAIR DEPOSITION SYSTEM	97593472
NATESTO N	90002018
NATESTO	86084664